Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Metastatic melanoma is a highly immunogenic tumor with very poor survival rates due to immune system escape-mechanisms. Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and the programmed death-1 (PD1) receptors, are being used to impede immune ev...

Full description

Bibliographic Details
Main Authors: Marta Morante, Atanasio Pandiella, Piero Crespo, Ana Herrero
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Biomolecules
Subjects:
RAS–ERK
melanoma
inhibitors
immunotherapy
Online Access:https://www.mdpi.com/2218-273X/12/11/1562

Similar Items

Similar Items